Dual antiretroviral therapies are effective and safe regimens in the central nervous system of neurologically symptomatic people living with HIV. (1st November 2020)

• Record Type: Journal Article
• Authors: Trunfio, Mattia; Rugge, Walter; Mighetto, Lorenzo; Vai, Daniela; Atzori, Cristiana; Nigra, Marco; Domini, Simone; Borgogno, Enrica; Guastamacchia, Giulia; Bonora, Stefano; Di Perri, Giovanni; Calcagno, Andrea
• Is Part Of: AIDS. Volume 34:Number 13(2020)
• Publication Date: 2020-11-01
• Subjects: biomarkers -- cerebrospinal fluid -- dual antiretroviral therapy -- HIV -- neurocognitive disorders -- viral escape -- viral suppression; AIDS (Disease) -- Periodicals; Acquired Immunodeficiency Syndrome; AIDS (Disease); Periodicals; Periodicals; 616.9792005
• DOI: 10.1097/QAD.0000000000002601
• Languages: English
• ISSNs: 0269-9370

Abstract

Abstract : Objective: Aim of this study was to compare cerebrospinal fluid (CSF) virological control, biomarkers and neurocognition of neurologically symptomatic patients on dual antiretroviral therapies (dual therapy) vs. 2 nucleoside reverse transcriptase inhibitors-based three-drug regimens (triple therapy). Design: Retrospective monocentric cross-sectional study. Methods: We analysed data from people living with HIV undergoing lumbar puncture for clinical/research reasons with plasma HIV-RNA less than 200 copies/ml and neurological/neurocognitive symptoms without significant contributing comorbidities. We measured CSF HIV-RNA, inflammation, blood–brain barrier integrity, neuronal damage and astrocytosis biomarkers (five biomarkers by ELISA and five indices by immunoturbidimetry) and recorded the neurocognitive performance (14 tests). CSF escape was defined as any case of CSF HIV-RNA 0.5 Log10 higher than viraemia or any case of detectable CSF HIV-RNA coupled with undetectable viraemia. Results: A total of 78 patients on triple therapy and 19 on dual therapy were included. Overall, 75.3% male, median age 51 years (46–58), current CD4 + count 545 cells/μl (349–735), time on current regimens 18 months (8–29), but length of plasma suppression 32 months (14–94). The two groups did not differ in terms of HIV-associated neurological diagnoses, demographic and viro-immunological features. Undetectable CSF HIV-RNA (73.7% in dual therapy vs. 78.2% in triple therapy, p.67) and CSF escape (21.1% in dual therapy vs. 19.2% in triple therapy, p.86) did not differ. No difference was observed in depression, anxiety, neurocognition (in 63 participants) nor in any tested biomarker. Conclusion: In people living with HIV with neurological/neurocognitive symptoms, peripherally effective dual therapy can show CSF virosuppression, inflammation, neuronal and astrocyte integrity and neurocognition comparable to triple therapy. Abstract : Supplemental Digital Content is available in the text